Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Drilon

Showing results (41-50 of 268) with videos related to

Pageof 27
Sort By:
JCO Precision Oncology|December 7, 2020
Lorlatinib and Bevacizumab Activity in <i>ALK-</i>Rearranged Lung Cancers After Lorlatinib ProgressionNoura J Choudhury, Robert J Young, Matthew Sellitti, et al.
Cancer Treatment Reviews|February 17, 2020
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failuresAlex Friedlaender, Alexander Drilon, Glen J Weiss, et al.
Cancer Treatment Reviews|September 15, 2022
Refining patient selection of MET-activated non-small cell lung cancer through biomarker precisionGillianne G Y Lai, Robin Guo, Alexander Drilon, et al.
Nature Reviews. Clinical Oncology|June 10, 2020
MET-dependent solid tumours - molecular diagnosis and targeted therapyRobin Guo, Jia Luo, Jason Chang, et al.
Cancers|August 26, 2023
<i>RET</i>-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy ActivityAntoine Desilets, Matteo Repetto, Soo-Ryum Yang, et al.
Head and Neck Pathology|October 16, 2021
Secretory Carcinoma of the Thyroid in a 49-Year-Old Man Treated with Larotrectinib: Protracted Clinical Course of Disease Despite the High-Grade Histologic FeaturesMaelle Saliba, Abhinita S Mohanty, Alan L Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2017
<i>RASA1</i> and <i>NF1</i> are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK InhibitionTakuo Hayashi, Patrice Desmeules, Roger S Smith, et al.
Nature Reviews. Clinical Oncology|November 15, 2017
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapesAlexander Drilon, Zishuo I Hu, Gillianne G Y Lai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 22, 2023
In Reply to "Selpercatinib Controls Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC"Yonina R Murciano-Goroff, Sabrina T Lin, Clare Wilhelm, et al.
Nature Reviews. Clinical Oncology|August 8, 2020
ROS1-dependent cancers - biology, diagnostics and therapeuticsAlexander Drilon, Chelsea Jenkins, Sudarshan Iyer, et al.
Pageof 27

Showing results (41-50 of 268) with videos related to

Sort By:
Pageof 27
JCO Precision Oncology|December 7, 2020
Lorlatinib and Bevacizumab Activity in <i>ALK-</i>Rearranged Lung Cancers After Lorlatinib ProgressionNoura J Choudhury, Robert J Young, Matthew Sellitti, et al.
Cancer Treatment Reviews|February 17, 2020
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failuresAlex Friedlaender, Alexander Drilon, Glen J Weiss, et al.
Cancer Treatment Reviews|September 15, 2022
Refining patient selection of MET-activated non-small cell lung cancer through biomarker precisionGillianne G Y Lai, Robin Guo, Alexander Drilon, et al.
Nature Reviews. Clinical Oncology|June 10, 2020
MET-dependent solid tumours - molecular diagnosis and targeted therapyRobin Guo, Jia Luo, Jason Chang, et al.
Cancers|August 26, 2023
<i>RET</i>-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy ActivityAntoine Desilets, Matteo Repetto, Soo-Ryum Yang, et al.
Head and Neck Pathology|October 16, 2021
Secretory Carcinoma of the Thyroid in a 49-Year-Old Man Treated with Larotrectinib: Protracted Clinical Course of Disease Despite the High-Grade Histologic FeaturesMaelle Saliba, Abhinita S Mohanty, Alan L Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2017
<i>RASA1</i> and <i>NF1</i> are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK InhibitionTakuo Hayashi, Patrice Desmeules, Roger S Smith, et al.
Nature Reviews. Clinical Oncology|November 15, 2017
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapesAlexander Drilon, Zishuo I Hu, Gillianne G Y Lai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 22, 2023
In Reply to "Selpercatinib Controls Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC"Yonina R Murciano-Goroff, Sabrina T Lin, Clare Wilhelm, et al.
Nature Reviews. Clinical Oncology|August 8, 2020
ROS1-dependent cancers - biology, diagnostics and therapeuticsAlexander Drilon, Chelsea Jenkins, Sudarshan Iyer, et al.
Pageof 27